ENTA 10-K: SEC filing

Enanta Pharmaceuticals

Filed with the SEC on · accession 0001193125-26-466170

ENTA filed a 10-K (annual report) with the SEC on Nov 18, 2026. The yearly report: full audited financial statements, the business, its risks and what management thinks about the year.

Summary of the filing

Enanta Pharmaceuticals filed its annual Form 10-K for fiscal year 2026, reporting financial results and business developments including pipeline progress in virology and immunology and royalty monetization agreements.

Key details

Partner/collaboratorAbbVie
Royalty purchase agreement counterpartyOMERS

✦ Ask GOAX AI about this filing — what it means for ENTA, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for ENTA?

Click here

Frequently asked questions

What did ENTA file with the SEC on Nov 18, 2026?

ENTA filed a 10-K (SEC filing). Enanta Pharmaceuticals filed its annual Form 10-K for fiscal year 2026, reporting financial results and business developments including pipeline progress in virology and immunology and royalty monetization agreements.

How do I read a 10-K?

The yearly report: full audited financial statements, the business, its risks and what management thinks about the year. Start with "Management’s Discussion and Analysis" (MD&A): management explains the year in their own words. Read "Risk Factors" for new risks — compare with last year’s list.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 10-K (annual report): The yearly report: full audited financial statements, the business, its risks and what management thinks about the year.

Other ENTA SEC filings

Get alerts when ENTA files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days